Key result
Oligosaccharides show preclinical potential to slow atherosclerosis progression and lower residual CV risk.
Why the study?
There is an urgent need for novel therapeutics that can economically and effectively slow the progression of atherosclerosis due to increasing obesity, diabetes, and hyperlipidaemia cases.
Answers are grounded in this paper and cite their sources.
Oligosaccharides may offer a novel, cost-effective therapeutic strategy to reduce residual risk and slow the progression of atherosclerosis.
Atherosclerosis is the major cause of cardiovascular-disease-related death worldwide, resulting from the subendothelial accumulation of lipoprotein-derived cholesterol, ultimately leading to chronic inflammation and the formation of clinically significant atherosclerotic plaques. Oligosaccharides have been widely used in biomedical research and therapy, including tissue engineering, wound healing, and drug delivery. Moreover, oligosaccharides have been consumed by humans for centuries, and are cheap, and available in large amounts. Given the constantly increasing number of obesity, diabetes, and hyperlipidaemia cases, there is an urgent need for novel therapeutics that can economically and effectively slow the progression of atherosclerosis. In this review, we address the current state of knowledge in oligosaccharides research, and provide an update of the recent in vitro and in vivo experiments that precede clinical studies. The application of oligosaccharides could help to eliminate the residual risk after the application of other cholesterol-lowering medicines, and provide new therapeutic opportunities to reduce the associated burden of premature deaths because of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Dabravolski et al. (2023) conducted a review in Atherosclerosis. Oligosaccharides was evaluated. Oligosaccharides are highlighted as potential novel therapeutics to slow atherosclerosis progression and reduce residual cardiovascular risk based on recent in vitro and in vivo experiments.
Synapse has enriched 10 related papers. Consider them for comparative context: